Published in Gastroenterology on July 29, 2009
Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2012) 9.88
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int (2015) 1.50
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide. Clin J Am Soc Nephrol (2010) 1.36
Strategies targeting cAMP signaling in the treatment of polycystic kidney disease. J Am Soc Nephrol (2013) 1.33
Polycystic liver diseases: congenital disorders of cholangiocyte signaling. Gastroenterology (2011) 1.26
Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol (2014) 1.23
Somatostatin analog therapy for severe polycystic liver disease: results after 2 years. Nephrol Dial Transplant (2012) 1.20
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Altered store operated calcium entry increases cyclic 3',5'-adenosine monophosphate production and extracellular signal-regulated kinases 1 and 2 phosphorylation in polycystin-2-defective cholangiocytes. Hepatology (2012) 1.09
Isolated polycystic liver disease. Adv Chronic Kidney Dis (2010) 1.08
Treatment strategies and clinical trial design in ADPKD. Adv Chronic Kidney Dis (2010) 1.05
Pathophysiology, epidemiology, classification and treatment options for polycystic liver diseases. World J Gastroenterol (2013) 1.04
Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastroenterol Hepatol (2014) 1.03
Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology (2011) 1.00
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib. Hepatology (2012) 0.99
Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol (2012) 0.97
Tolvaptan plus pasireotide shows enhanced efficacy in a PKD1 model. J Am Soc Nephrol (2014) 0.94
Polycystic liver diseases. Dig Liver Dis (2010) 0.93
Complications arising in simple and polycystic liver cysts. World J Hepatol (2012) 0.88
Polycystic liver diseases: advanced insights into the molecular mechanisms. Nat Rev Gastroenterol Hepatol (2014) 0.87
New treatments for autosomal dominant polycystic kidney disease. Br J Clin Pharmacol (2013) 0.85
Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J Hepatol (2015) 0.84
Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease. Am J Kidney Dis (2013) 0.84
Insignificant effect of secretin in rodent models of polycystic kidney and liver disease. Am J Physiol Renal Physiol (2012) 0.84
A systematic review of the predictors of disease progression in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2015) 0.84
Current management of noninfectious hepatic cystic lesions: A review of the literature. World J Hepatol (2013) 0.83
Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 0.83
Everolimus and long acting octreotide as a volume reducing treatment of polycystic livers (ELATE): study protocol for a randomized controlled trial. Trials (2011) 0.82
Efficacy of 4 Years of Octreotide Long-Acting Release Therapy in Patients With Severe Polycystic Liver Disease. Mayo Clin Proc (2015) 0.82
Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2016) 0.81
An emerging molecular understanding and novel targeted treatment approaches in pediatric kidney diseases. Front Pediatr (2014) 0.81
ADPKD: Prototype of Cardiorenal Syndrome Type 4. Int J Nephrol (2010) 0.81
Semiautomated Segmentation of Polycystic Kidneys in T2-Weighted MR Images. AJR Am J Roentgenol (2016) 0.81
Clinical Correlates of Mass Effect in Autosomal Dominant Polycystic Kidney Disease. PLoS One (2015) 0.79
Volume regression of native polycystic kidneys after renal transplantation. Nephrol Dial Transplant (2015) 0.78
Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan. Clin Exp Nephrol (2014) 0.78
Rare cystic liver lesions: a diagnostic and managing challenge. World J Gastroenterol (2013) 0.77
The spectrum of autosomal dominant polycystic kidney disease in children and adolescents. Pediatr Nephrol (2016) 0.76
Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BMC Nephrol (2012) 0.76
Similar renal outcomes in children with ADPKD diagnosed by screening or presenting with symptoms. Pediatr Nephrol (2010) 0.76
Novel therapeutic approaches to autosomal dominant polycystic kidney disease. Transl Res (2014) 0.76
Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context. J Am Soc Nephrol (2016) 0.76
Development and Validation of a Disease-Specific Questionnaire to Assess Patient-Reported Symptoms in Polycystic Liver Disease. Hepatology (2016) 0.76
Experimental therapies and ongoing clinical trials to slow down progression of ADPKD. Curr Hypertens Rev (2013) 0.76
Heterotrimeric G protein signaling in polycystic kidney disease. Physiol Genomics (2016) 0.75
Night blindness in a haemodialysed ADPKD patient receiving octreotide. Clin Kidney J (2012) 0.75
Laparoscopic surgery and polycystic liver disease: Clinicopathological features and new trends in management. J Minim Access Surg (2016) 0.75
Polycystic Liver Disease: The Benefits of Targeting cAMP. Clin Gastroenterol Hepatol (2016) 0.75
Portal hypertension in polycystic liver disease patients does not affect wait-list or immediate post-liver transplantation outcomes. World J Gastroenterol (2016) 0.75
Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial. Trials (2015) 0.75
Medical therapy for polycystic liver disease. Ann R Coll Surg Engl (2016) 0.75
Somatotroph pituitary adenoma with acromegaly and autosomal dominant polycystic kidney disease: SSTR5 polymorphism and PKD1 mutation. Pituitary (2012) 0.75
Tolvaptan for the Treatment of Enlarged Polycystic Liver Disease. Case Rep Nephrol Dial (2017) 0.75
Cross-sectional prevalence of pancreatic cystic lesions in patients with acromegaly, a single-center experience. Pituitary (2017) 0.75
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med (2008) 7.22
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med (2006) 6.31
Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N Engl J Med (2013) 3.81
Gain of function Naν1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol (2011) 3.53
Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet (2005) 3.33
Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology (2014) 3.23
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology (2010) 3.02
Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol (2013) 2.98
Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study. Gut (2010) 2.91
Embolization of large spontaneous portosystemic shunts for refractory hepatic encephalopathy: a multicenter survey on safety and efficacy. Hepatology (2013) 2.64
Nucleotide-binding oligomerization domain-2 modulates specific TLR pathways for the induction of cytokine release. J Immunol (2005) 2.52
Histological diversity in cholangiocellular carcinoma reflects the different cholangiocyte phenotypes. Hepatology (2012) 2.49
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis. Nat Genet (2007) 2.48
Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology (2014) 2.27
Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome. Radiology (2013) 2.12
Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology (2007) 2.11
Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut (2013) 2.10
Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology (2013) 2.08
Endoscopic resection of ampullary lesions: a single-center 8-year retrospective cohort study of 91 patients with long-term follow-up. Surg Endosc (2013) 2.01
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology (2007) 1.95
Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol (2010) 1.91
NOD2 mediates anti-inflammatory signals induced by TLR2 ligands: implications for Crohn's disease. Eur J Immunol (2004) 1.90
Pain perception is altered by a nucleotide polymorphism in SCN9A. Proc Natl Acad Sci U S A (2010) 1.79
Everolimus does not further reduce polycystic liver volume when added to long acting octreotide: results from a randomized controlled trial. J Hepatol (2013) 1.79
Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl (2002) 1.79
Hepatitis E virus: an underestimated opportunistic pathogen in recipients of allogeneic hematopoietic stem cell transplantation. Blood (2013) 1.77
Serum creatine kinase as predictor of clinical course in rhabdomyolysis: a 5-year intensive care survey. Intensive Care Med (2003) 1.76
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
Long-term follow-up, clinical features, and quality of life in a series of 103 patients with hyperimmunoglobulinemia D syndrome. Medicine (Baltimore) (2008) 1.74
Entecavir shows limited efficacy in HBeAg-positive hepatitis B patients with a partial virologic response to adefovir therapy. J Hepatol (2008) 1.71
Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol (2007) 1.68
Short mucin 6 alleles are associated with H pylori infection. World J Gastroenterol (2006) 1.67
Improvement of autoimmune hepatitis during pregnancy followed by flare-up after delivery. Am J Gastroenterol (2002) 1.66
Young women with polycystic liver disease respond best to somatostatin analogues: a pooled analysis of individual patient data. Gastroenterology (2013) 1.66
Predicting intracranial traumatic findings on computed tomography in patients with minor head injury: the CHIP prediction rule. Ann Intern Med (2007) 1.65
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Insulin resistance and response to telaprevir plus peginterferon α and ribavirin in treatment-naive patients infected with HCV genotype 1. Gut (2012) 1.63
Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology (2004) 1.59
The Global Rating Scale in clinical practice: a comprehensive quality assurance programme for endoscopy departments. Dig Liver Dis (2012) 1.59
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. Hepatology (2005) 1.59
Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl (2010) 1.59
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Secondary, somatic mutations might promote cyst formation in patients with autosomal dominant polycystic liver disease. Gastroenterology (2011) 1.58
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol (2013) 1.57
Arm raising at exposure-controlled multidetector trauma CT of thoracoabdominal region: higher image quality, lower radiation dose. Radiology (2008) 1.56
Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial. J Hepatol (2006) 1.54
The spectrum of nonadherence with medication in heart, liver, and lung transplant patients assessed in various ways. Transpl Int (2011) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
The influence of baseline characteristics on viral dynamic parameters in chronic hepatitis B patients treated with lamivudine. J Hepatol (2002) 1.48
Diagnosis and management of polycystic liver disease. Nat Rev Gastroenterol Hepatol (2013) 1.46
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Noncirrhotic presinusoidal portal hypertension is common in cystic fibrosis-associated liver disease. Hepatology (2011) 1.43
Evaluation of hepatic cystic lesions. World J Gastroenterol (2013) 1.43
GC-MS analysis of breath odor compounds in liver patients. J Chromatogr B Analyt Technol Biomed Life Sci (2008) 1.40
Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation (2009) 1.38
Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. Gastroenterology (2009) 1.38
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
Long-term risk of acute diverticulitis among patients with incidental diverticulosis found during colonoscopy. Clin Gastroenterol Hepatol (2013) 1.35
Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature. Dig Dis Sci (2009) 1.34
Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol (2006) 1.32
Deletion mutation of sodium channel Na(V)1.7 in inherited erythromelalgia: enhanced slow inactivation modulates dorsal root ganglion neuron hyperexcitability. Brain (2011) 1.32
Comparison of five segmentation tools for 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.31
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
Patients with isolated polycystic liver disease referred to liver centres: clinical characterization of 137 cases. Liver Int (2011) 1.30
Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology (2011) 1.29
Beneficial response to interleukin 1 receptor antagonist in traps. Am J Med (2004) 1.29
Minor head injury: guidelines for the use of CT--a multicenter validation study. Radiology (2007) 1.28
A novel iterative method for lesion delineation and volumetric quantification with FDG PET. Nucl Med Commun (2007) 1.27
Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med (2009) 1.26
2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. J Clin Oncol (2005) 1.26
IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys (2006) 1.26
Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc Natl Acad Sci U S A (2009) 1.25
Association between Toll-like receptor 4 and inflammatory bowel disease. Inflamm Bowel Dis (2005) 1.24
Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int (2006) 1.24
Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol (2006) 1.24
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer Lett (2012) 1.24
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin Pharmacol Ther (2004) 1.23
Diagnostic performance of selected commercial HEV IgM and IgG ELISAs for immunocompromised and immunocompetent patients. J Clin Virol (2013) 1.22
Primary sclerosing cholangitis is associated with a distinct phenotype of inflammatory bowel disease. Inflamm Bowel Dis (2012) 1.21
Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology (2010) 1.21
Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care (2006) 1.21
Expression of multidrug resistance-associated protein 1 in hepatocellular carcinoma is associated with a more aggressive tumour phenotype and may reflect a progenitor cell origin. Liver Int (2008) 1.20
Prospective study comparing different indirect methods to measure portal pressure. J Vasc Interv Radiol (2011) 1.20
Investigating the origin and spread of hepatitis C virus genotype 5a. J Virol (2006) 1.16
Diffusion-weighted MRI provides additional value to conventional dynamic contrast-enhanced MRI for detection of hepatocellular carcinoma. Eur Radiol (2009) 1.16
MELD score to predict outcome in adult patients with non-acetaminophen-induced acute liver failure. Liver Int (2007) 1.13
Acute-on-chronic liver failure: current concepts on definition, pathogenesis, clinical manifestations and potential therapeutic interventions. Expert Rev Gastroenterol Hepatol (2011) 1.13
Generic and disease-specific health related quality of life in non-cirrhotic, cirrhotic and transplanted liver patients: a cross-sectional study. BMC Gastroenterol (2003) 1.13
Crohn's disease patients homozygous for the 3020insC NOD2 mutation have a defective NOD2/TLR4 cross-tolerance to intestinal stimuli. Immunology (2007) 1.12
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis (2012) 1.12